Say goodbye to transplant immune tolerance! Type 1 diabetes says goodbye to anti-rejection drugs

For decades, immunologists have made universal immune tolerance a major goal in transplant medicineA recent preclinical study published in Nature Communications offers new hope for universal transplant immune tolerancehttps://doi.org/10.1038/s41467-019-11338-yorgan transplant, more disappointment than hope?for many patients with end-stage organ failure, organ transplants may be the only hope of survivalIn order to prevent transplant rejection, the recipient must take drugs that suppress the body's immune system for a long timeThese immunosuppressive drugs can effectively prevent rejection in the short termHowever, because anti-rejection drugs are not specific to suppress the immune system, people who take these drugs often face a serious infection or even a risk of cancerIn addition, anti-rejection drugs also have many non-immune side effects of immunosuppression, such as leading to high blood pressure, nephrotoxicity, diarrhea and diabetesMore seriously, many recipients may even disappear due to the poor effectiveness of immunosuppressive drugs in long-term prevention of transplant rejectionthe efforts of generations
as transplant recipients suffering from long-term immunosuppression are increasing, generations of immunologists have made immune tolerance a major goal in the field of transplant medicineAfter all, organs are hard-won, can not be wasted in vain, and the recipient sits at a great cost, need to see the quality of life and the return of survivalrecently, researchers from the Department of Surgery at the University of Minnesota School of Medicine and researchers from the Schulze Diabetes Institute and Northwestern University collaborated on a new study that solved the problem in the inhuman primate experimentbid farewell to anti-rejection drug dependencethe study used the unique properties of improved donor white blood cells to carefully simulate the preclinical transplant environment with rhesus macaques as the subjectsThe researchers injected these cells into the transplant recipient a week before and one day after the transplant, reproducing the body's tolerance to its own tissues and organs in a natural state After the transplant, the anti-rejection drug was completely discontinued for 21 days, and the transplanted islet remained functional "Our study is the first, reliable, and safely induced non-human primate study to induce long-lasting transplant immunity, and the success of non-human primates gives us hope that the results will be confirmed in human clinical islet and live kidney transplantation, opening a new era in transplant medicine Bernhard Hering, senior author of the study and a professor in the Department of Surgery at the University of Minnesota, said New hope for type 1 diabetes for many people with type 1 diabetes, islet cell transplantation may become the first choice for treatment and become a potential cure for a complete cure, overcoming long-term anti-rejection drugs and such exciting research is only a step away from human realization references: s1 s researchers remove for anti-defit drugs in the country of the 2 s- long-term tolerance of islet allografts in non human human inducsed by apoptotic donor leukocytes